Given that alterations in sphingolipid and thiamine metabolism were most prominent at the early stage of BCR::ABL1 expression, we hypothesize that dysregulation of these two metabolic pathways may be associated with the initiation of CML [28]. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.